Study to Evaluate the Immunogenicity and Safety of LBVD(Hexavalent Vaccine), Given to Healthy Infants at Primary Series

Inclusion Criteria: * Infants in stable health * Male or female 6 to 8 weeks of age * Signed informed consent by the infant's parent(s) or legally acceptable representative(s) Exclusion Criteria: * Known or suspected Hib, HepB, diphtheria, tetanus, pertussis, or poliomyelitis * Fever ≥ 38.0℃/100.4℉ within 3 days prior to study registration * Known or suspected immunodeficiency * Previous use of blood or blood-derived products * Previous use of any diphtheria, tetanus, pertussis-based combination vaccine(s), Hib conjugate, poliovirus, or combination * Household contact or intimate exposure with a confirmed case of Hib, HepB, diphtheria, pertussis, tetanus or poliomyelitis within 30 days prior to study registration * Any history of allergy (hypersensitivity) to any of the vaccine components * Participation in another interventional clinical trial simultaneously